These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

807 related items for PubMed ID: 27635672

  • 1. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Ito T, Lee L, Jensen RT.
    Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
    [Abstract] [Full Text] [Related]

  • 2. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R, Lang B, Wong H, Chiu J, Yat WK, Shek T, Cho WY, Yau LC, Yau T.
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [Abstract] [Full Text] [Related]

  • 3. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT, Kunz PL, Reidy-Lagunes DL.
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [Abstract] [Full Text] [Related]

  • 4. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F.
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, Sherriff D, Napier M, Ramage J, Hoyle M.
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [Abstract] [Full Text] [Related]

  • 7. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH.
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [Abstract] [Full Text] [Related]

  • 8. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK, Khan MS, Toumpanakis C, Caplin ME.
    Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
    [Abstract] [Full Text] [Related]

  • 9. Management of neuroendocrine tumors.
    Chung C.
    Am J Health Syst Pharm; 2016 Nov 01; 73(21):1729-1744. PubMed ID: 27769969
    [Abstract] [Full Text] [Related]

  • 10. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K, Lamberts SW.
    Endocr Relat Cancer; 2016 Dec 01; 23(12):R551-R566. PubMed ID: 27697899
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H.
    Int J Mol Sci; 2019 Jun 22; 20(12):. PubMed ID: 31234481
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
    Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura Á, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P.
    BMC Cancer; 2015 Jul 04; 15():495. PubMed ID: 26138480
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, Chen Z, Brutcher E, Renfroe M, El-Rayes BF.
    Cancer; 2018 May 01; 124(9):1992-2000. PubMed ID: 29451701
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.
    Ito T, Jensen RT.
    Expert Opin Pharmacother; 2021 Apr 01; 22(6):685-693. PubMed ID: 33131345
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
    Ruggeri RM, Benevento E, De Cicco F, Fazzalari B, Guadagno E, Hasballa I, Tarsitano MG, Isidori AM, Colao A, Faggiano A, NIKE Group.
    J Endocrinol Invest; 2023 Feb 01; 46(2):213-234. PubMed ID: 36038743
    [Abstract] [Full Text] [Related]

  • 20. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
    Sood A, Munir M, Syed O, Mehta V, Kaur R, Kumar A, Sridhar A, Sood A, Gupta R.
    Expert Opin Drug Saf; 2024 Aug 01; 23(8):949-957. PubMed ID: 38847075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.